Company Overview
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1 and DARE-PTB1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB2 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. It has a strategic collaboration with MyMenopauseRx. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
Recent Developments
- Dec 2025 Revenue of $1.03M (+10429.4% YoY); net profit $-13.40M.
- Trailing 12 Months Year-on-year growth — revenue +499.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 6.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 6.45% |
| 1 Year: | 499.60% |
Stock Price Performance
| 1 Year: | -66.21% |
| 6 Months: | -53.40% |
| 3 Months: | -61.46% |
| 1 Month: | -49.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)26.92 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 78.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DARE Daré Bioscience, Inc. PHARMA | 0.71 | -1.08 | $13.97M | 0.00% | - | - | 6.45% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | - | 10.00M | 0 | 0 | 0 | 1.00M | 9.30K | 22.44K | 41.69K | 25.43K | - | 2.26K | 152.46K |
| Operating Income | - | - | - | - | - | - | - | - | - | - | -5.96K | - | -228.46K | -479.62K | -1.33M | -7.68M | -3.62M | -2.62M | -3.08M | -3.98M | -3.42M | -4.25M | -7.13M | -7.58M | -7.69M | -9.16M | -12.67M | -8.40M | 384.32K | -7.14M | -8.38M | -8.99M | -8.40M | -6.02M | -7.36M | -4.68M | -4.58M | -3.83M | -3.67M | -3.00M |
| Net Income | -2.91M | -7.40M | -5.56M | -7.47M | -8.42M | -9.91M | -10.55M | -10.72M | -13.54M | -10.86M | -16.11K | -4.95M | -243.86K | -498.19K | -1.63M | -7.67M | -3.58M | -2.57M | -3.05M | -3.95M | -3.39M | -4.25M | -7.12M | -7.58M | -7.32M | -9.16M | -12.67M | -8.40M | 414.00K | -7.02M | -8.04M | -8.76M | -8.30M | -6.76M | 12.91M | -4.70M | -4.38M | -4.02M | -3.56M | -3.00M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.27 | -0.24 | -0.16 | -0.18 | -0.18 | -0.10 | 0.00 | -0.08 | -0.09 | -1.22 | -1.09 | -0.81 | 1.52 | -0.55 | -0.50 | -0.45 | -0.28 | -0.21 |
| R&D Expense | 1.50M | 2.65M | 2.93M | 4.70M | 5.02M | 6.68M | 7.09M | 7.16M | 9.77M | 7.52M | 7.09M | 3.18M | 27.80K | 3.58K | 280.79K | 1.09M | 2.22M | 1.45M | 1.69M | 2.51M | 1.97M | 2.38M | 5.55M | 6.20M | 5.73M | 7.34M | 10.43M | 5.81M | 6.80M | 4.46M | 5.02M | 6.04M | 6.67M | 3.35M | 4.93M | 2.68M | 2.30M | 1.43M | 1.18M | 660.46K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 625.00K | 6.00K | 80.00K | - | 766.00K | - | - | - | - | 0 | 10.00M | 2.81M | 9.78K | 1.03M |
| Operating Income | - | - | - | - | -630.59K | -11.18M | -16.88M | -14.34M | -27.40M | -39.07M | -31.39M | -30.94M | -23.45M | -13.55M |
| Net Income | -22.10M | -17.14M | -23.34M | -39.59M | -672.69K | -11.50M | -16.74M | -14.26M | -27.40M | -38.70M | -30.95M | -30.16M | -4.05M | -13.40M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.91 | -0.63 | -0.37 | -4.15 | -0.48 | -1.20 |
| R&D Expense | 15.81M | 9.70M | 11.77M | 25.95M | 72.67K | 984.75K | 6.41M | 8.55M | 20.77M | 30.62M | 30.04M | 21.54M | 14.31M | 5.52M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 6.83M | 53.39M | 78.22M | 44.61K | 14.26M | 7.83M | 7.44M | 7.55M | 55.81M | 43.83M | 21.28M | 22.10M | 32.47M |
| Total Equity | -58.40M | -80.04M | -94.30M | 45.33M | -46.95K | -710.62K | 13.29M | 6.73M | 440.83K | -1.15M | 38.75M | 11.11M | -5.05M | -6.01M | 2.84M |
| Cash & Equivalents | 15.35M | 16.71M | 5.49M | 51.17M | 219.41K | 44.61K | 7.56M | 6.81M | 4.78M | 4.67M | 51.67M | 34.67M | 10.48M | 15.70M | 24.71M |
| Total Liabilities | - | - | - | - | - | 755.24K | 967.04K | 1.10M | 7.00M | 8.70M | 17.05M | 32.71M | 26.33M | 28.11M | 29.63M |
| Current Liabilities | - | - | 15.15M | 8.06M | 16.34M | 755.24K | 966.65K | 1.09M | 5.61M | 7.66M | 16.05M | 31.62M | 20.48M | 21.61M | 23.69M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | -2.54M | -10.27M | -13.32M | -25.23M | -28.76M | -18.09M | -38.86M | 5.47M | -9.89M |
| Investing Cash Flow | - | - | - | - | - | 9.92M | -518.84K | 6.14M | -17.62K | -14.52K | -63.07K | -629.43K | -573.05K | -385.28K |
| Financing Cash Flow | - | - | - | - | - | 155.00K | 10.11M | 5.15M | 25.13M | 75.85M | 1.34M | 15.64M | 354.52K | 19.28M |
| Capital Expenditure | -180.00K | -7.00K | -225.00K | -277.00K | -535.00K | -0 | -11.84K | -0 | -17.62K | -14.52K | -63.07K | -629.43K | -573.05K | -385.28K |
| Free Cash Flow | - | - | - | - | - | -2.54M | -10.28M | -13.32M | -25.25M | -28.78M | -18.15M | -39.49M | 4.90M | -10.27M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -82.3% | - | - | - | - | - | -313.9% | -1,101.9% | -239,692.2% | -1,315.5% |
| Net Margin % | -3,536.2% | -285,716.7% | -29,177.5% | - | -87.8% | - | - | - | - | - | -309.5% | -1,074.2% | -41,430.9% | -1,300.7% |
| ROE % | 27.6% | 18.2% | -51.5% | 84,337.7% | 94.7% | -86.5% | -248.8% | -3,235.7% | 2,379.1% | -99.8% | -278.5% | 597.5% | 67.4% | -471.4% |
| ROCE % | - | - | - | - | 88.7% | -84.1% | -250.6% | -783.7% | 24,936.3% | -98.3% | -257.2% | -3,858.9% | -4,805.0% | -154.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 3.26% | 640.88K | $502.64K |
| 2 | Geode Capital Management, LLC | 0.71% | 140.09K | $109.87K |
| 3 | US BANCORP \DE\ | 0.61% | 120.92K | $94.84K |
| 4 | Vanguard Fiduciary Trust Co | 0.46% | 91.27K | $71.58K |
| 5 | Blackrock Inc. | 0.33% | 64.25K | $50.39K |
| 6 | State Street Corporation | 0.24% | 47.41K | $37.19K |
| 7 | Jane Street Group, LLC | 0.18% | 36.09K | $28.31K |
| 8 | Northern Trust Corporation | 0.17% | 34.21K | $26.83K |
| 9 | HRT Financial LP | 0.11% | 22.43K | $17.59K |
| 10 | Virtu Financial LLC | 0.08% | 15.80K | $12.39K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DARE
Dare Bioscience, Inc. SEC Filing (Sep 4, 2026) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOd2tpQ0kxejVnQ0RVdHV1aTJkcVg5ZnF0cWNKVTh4V0w1WGJ3Q3ZUcG1vNFhqYjFZWnhWbllvQ1lMdi0xNzBQaTRDdmM5Mnl3ZDQ3TGZjWGJESmxNOENMOUdjYXRtTS0xTVlCdzZnZVFKWkdMbk5YaEZnMk85NlY3ZWthcW85WWY2NndWQm…
DARE Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9QY2VtQU1SNnR1TlI4QUNYMXlSakp0MktpTjNwdWtVTGVxRHdnUWFybExtRjVsMGstZm5ra0FCM0tVaWdoV1cwNzR2Wk84SDhudTdPcmQ2ZjNhWWJMY0oxcXhka2s0bGJUYWtyV1g3TlRaajlhM3NZRlNR?oc=5" target="_blank">DAR…
Passive-Investing Boom Is Making Life Harder for Stock Pickers - Bloomberg.com
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNZFJFcE1TLV9nT0E2RDBSUTYyNnh6cFhKbVR2RlJmQ0FCeDZJblJaal9uUm1sVWhic1Z1bkpfcW53S0lQb0h5WEJacGZvaGJKY3BIOEJEbi1CTVdqTGNCSlRlSlZKem1SSE16SWdEU0ktXzRxdEpZa1U4XzFkLS11WkV4dTczUEZVZ0NzMk…
Daré Bioscience Announces $6.0 Million Registered Direct Offering and Concurrent Private Placement - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNMWh6ZHI4OHk3T1JuWGxnbWJ4VXAzZkVBUTVCQ0FaUnU4NUxyZnRUcXNJaWdKdjRrS2lTeEFJOEtZdjhocm5tWG5qX0VxSDU2SWZ3Z3lnZ3Y3d0VOdWg1OFE4c3RWLWJpS1NWTUVqdWVOOWVYWTNrWS1mUzRJWUZ0cC1KMWk3ZVdtUXBPbE…
Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxNV1dZTVJpcGRpUS1tTVhtZi1Tc3VRbEpWN3VtZ2lUaVc0NmVzamZ0RmEybTRkbzhfRWltb3FMcktEM3ZLQ0dyRnFjWm9LNVV5QzY3eTQ1RUlISHIyUnlnMFVSajlIS0I2d3ZZbmdOR0loN1RLSUNoUW5wRnItNFJVbUt2cWMwVTBOZGU1Vn…
Dare Bioscience Inc (DARE) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOcE8zY2dpYnpqamZQR19Cc0NNaDBad1dlczVlbk5NNVVvUTdpaGNnQm0yNlJKa2J2Z3NnTWhPT1NuejBBbFNsUXVVZ19JNExWNXlEZG5GdnRQNjYwajJ4amh5MWQySV90dTNkZXhDYWQyaXBZby12UEV6T0VKVmNiTkJkeHl5X0ZUMG1adm…
DARE — Frequently Asked Questions
What is the current share price of Daré Bioscience, Inc. (DARE)?
As of 2026-09-19 21:16 PDT, Daré Bioscience, Inc. (DARE) trades at $0.71 on NasdaqCM. Its 52-week range is $0.71 to $3.27.
What is the market capitalisation of DARE?
Daré Bioscience, Inc. (DARE) has a market capitalisation of $13.97M on NasdaqCM.
What is the P/E ratio of DARE?
DARE trades at a trailing price-to-earnings (P/E) ratio of -1.08. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -19.37.
Is DARE a good stock to buy?
This page provides a data-driven analysis of Daré Bioscience, Inc. (DARE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.